ANAPTYSBIO, INC. (ANAB) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Current obligations | 35.35M USD | Liabilities, Current |
| Cash and equivalents | 133.83M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 30.32M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $35.35M | $133.83M | $30.32M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $41.70M | $248.47M | $37.99M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $38.63M | $238.20M | $73.44M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $38.10M | $109.83M | $139.12M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $35.53M | $44.30M | $221.41M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $44.04M | $98.64M | $241.30M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $45.43M | $123.08M | $262.29M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $43.88M | $191.58M | $238.54M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $40.42M | $71.82M | $278.98M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $32.30M | $53.70M | $300.97M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $37.44M | $35.97M | $354.94M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $39.18M | $26.30M | $386.75M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $41.63M | $35.21M | $394.28M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $35.80M | $94.56M | $336.59M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $26.05M | $71.31M | $369.93M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $21.06M | $58.55M | $384.42M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $19.87M | $71.70M | $370.45M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $19.78M | $166.41M | $339.21M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $16.10M | $495.73M | $52.37M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $20.89M | $336.33M | $37.74M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $20.62M | $332.25M | $58.60M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $14.47M | $284.15M | $96.21M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $19.82M | $250.46M | $143.20M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $24.47M | $209.15M | $129.19M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $20.13M | $221.17M | $156.71M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $23.25M | $165.32M | $197.17M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $29.54M | $171.02M | $203.21M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $29.73M | $182.90M | $238.10M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $30.62M | $146.55M | $275.66M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $24.75M | $105.85M | $309.81M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $21.84M | $113.60M | $313.49M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $20.87M | $293.41M | $200.41M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $16.79M | $57.06M | $210.85M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $14.34M | $69.47M | $178.69M | (m) | (m) | (m) |
| 2017-12-31 | (m) | $14.09M | $81.19M | $167.22M | (m) | (m) | (m) |
| 2017-09-30 | (m) | $11.17M | $26.67M | $89.05M | (m) | (m) | (m) |
| 2017-06-30 | (m) | $10.08M | $30.75M | $75.61M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $8.13M | $96.75M | $6.74M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $5.71M | $51.23M | $0.00 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |